Immunopathology of secondary-progressive multiple sclerosis

Annals of Neurology

Volumn 50, Issue 5, 2001, Pages 646-657

  Prineas, John W ^a   Kwon, Eunice E ^b   Cho, Eun Sook ^b   Sharer, Leroy R ^b   Barnett, Michael H ^a   Oleszak, Emilia L ^c   Hoffman, Brad ^c   Morgan, Bryan P ^d  

^a UNIVERSITY OF SYDNEY   (Australia)

^b RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

^c TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT COMPONENT C3D; MYELIN;

ADULT; ARTICLE; CASE REPORT; DEMYELINATION; DISEASE COURSE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOPATHOGENESIS; MALE; MICROGLIA; MULTIPLE SCLEROSIS; PHAGOCYTOSIS; PRIORITY JOURNAL;

ADULT; ANTIGENS, DIFFERENTIATION; CEREBELLUM; COMPLEMENT C3; COMPLEMENT C3D; COMPLEMENT MEMBRANE ATTACK COMPLEX; CORPUS CALLOSUM; DISEASE PROGRESSION; HUMANS; IMMUNOGLOBULINS; IMMUNOHISTOCHEMISTRY; MACROPHAGES; MALE; MICROGLIA; MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE; MYELIN SHEATH; OLIGODENDROGLIA;

EID: 0034765063     PISSN: 03645134     EISSN: None     Source Type: Journal    
DOI: 10.1002/ana.1255     Document Type: Article

References (70)

1. Assessment of lesion pathology in multiple sclerosis using quantitative MRI morphometry and magnetic resonance spectroscopy
2. Use of proton magnetic resonance spectroscopy for monitoring disease progression in multiple sclerosis
3. The longstanding MS lesion. A quantitative MRI and electron microscopic study
4. Axonal damage correlates with disability in patients with relapsing-remitting multiple sclerosis. Results of a longitudinal magnetic resonance spectroscopy study
5. Neurodegeneration in multiple sclerosis: Relationship to neurological disability
6. Axonal damage in acute multiple sclerosis lesions
7. Axonal transection in the lesions of multiple sclerosis
8. Progressive cerebral atrophy in multiple sclerosis. A serial MRI study
9. Magnetic resonance imaging in the monitoring of disease progression in multiple sclerosis
10. Axonal pathology in myelin disorders
11. A comparison of the pathology of primary and secondary progressive multiple sclerosis
12. Microglia in degenerative neurological disease
13. Monocyte/macrophage differentiation in early multiple sclerosis lesions
14. Distribution of immunoglobulin superfamily members ICAM-1, -2, -3, and the beta 2 integrin LFA-1 in multiple sclerosis lesions
15. Matrix metalloproteinases in the normal human central nervous system, microglial nodules, and multiple sclerosis lesions
16. On classification of post-mortem multiple sclerosis plaques for neuroscientists
17. The fine structure of chronically active multiple sclerosis plaques
18. On the immunopathology of plaque development and repair in multiple sclerosis
19. Attachment of myelin to coated pits on macrophages in experimental allergic encephalomyelitis
20. Further ultrastructural observations of virus morphogenesis and myelin pathology in JHM virus encephalomyelitis
21. Evidence for activation of the terminal pathway of complement and upregulation of sulfated glycoprotein (SGP)-2 in the hypoglossal nucleus following peripheral nerve injury
22. Reactive microglia in multiple sclerosis lesions have an increased expression of receptors for the Fc part of IgG
23. Phenotypic differences between human monocytes/macrophages and microglial cells studied in situ and in vitro
24. Cytoplasmic tails of human complement receptor type 3 (CR3, CD11b/CD18) regulate ligand avidity and the internalization of occupied receptors
25. Anti-macrophage CR3 antibody blocks myelin phagocytosis by macrophages in vitro
26. A role for complement in phagocytosis of myelin
27. Opsonization of normal myelin by anti-myelin antibodies and normal serum
28. Receptor-mediated phagocytosis of myelin by macrophages and microglia: Effect of opsonization and receptor blocking agents
29. Macrophage phagocytosis of myelin in vitro determined by flow cytometry: Phagocytosis is mediated by CR3 and induces production of tumor necrosis factor-alpha and nitric oxide
30. Activation of adult human derived microglia by myelin phagocytosis in vitro
31. Immunology of multiple sclerosis
32. Biochemistry of demyelination
33. The expression of tissue-type plasminogen activator, matrix metalloproteases and endogenous inhibitors in the central nervous system in multiple sclerosis: Comparison of stages in lesion evolution
34. Characterization and distribution of phagocytic macrophages in multiple sclerosis plaques
35. Cytokine mRNA expression in inflammatory multiple sclerosis lesions: Detection by non-radioactive in situ hybridization
36. Complement potentiates the degradation of myelin proteins by plasmin: Implications for a mechanism of inflammatory demyelination
37. Proteolytic enzyme activity of blood leukocytes and cerebrospinal fluid in multiple sclerosis
38. Gelatinase B is present in the cerebrospinal fluid during experimental autoimmune encephalomyelitis and cleaves myelin basic protein
39. Axonal damage in a model of an MS lesion
40. B cells and autoimmunity
41. Demyelination in primate autoimmune encephalomyelitis and acute multiple sclerosis lesions: A case for antigen-specific antibody mediation
42. Antibodies to myelinoligodendrocyte glycoprotein in cerebrospinal fluid from patients with multiple sclerosis and controls
43. Augmentation of demyelination in rat acute allergic encephalomyelitis by circulating mouse monoclonal antibodies directed against a myelin/oligodendrocyte glycoprotein
44. Sera from MS patients and normal controls opsonize myelin
45. Heterogeneity of multiple sclerosis lesions: Implications for the pathogenesis of demyelination
46. Multiple sclerosis: In situ evidence for antibody- and complement-mediated demyelination
47. Binding of normal human IgG to myelin sheaths, glia and neurons
48. Isolation of membrane attack complex of complement from myelin membranes treated with serum complement
49. Complement activation by isolated myelin: Activation of the classical pathway in the absence of myelin-specific antibodies
50. Effects of humoral factors on myelin in organotypic cultures
51. The instructive role of innate immunity in the acquired immune response
52. Complement activation by beta-amyloid in Alzheimer disease
53. Interleukin-1 expression in different plaque types in Alzheimer's disease: Significance in plaque evolution
54. Neurofibrillary tangles of Guam parkinson-dementia are associated with reactive microglia and complement proteins
55. Alzheimer's disease: Coated vesicles, coated pits and the amyloid-related cell
56. The complex of microglial cells and amyloid star in three-dimensional reconstruction
57. Amyloid-β immunization results in decreased Aβ deposition in the brains of APP-PS1 mice
58. Biotechnological agents for the immunotherapy of multiple sclerosis. Principles, problems and perspectives
59. Fc receptors of microglial lipophages in multiple sclerosis
60. Expression of transforming growth factor (TGF)-β1, -β2, and -β3 isoforms and TGF-β type I and type II receptors in multiple sclerosis lesions and human adult astrocyte cultures
61. The pathophysiology of acute optic neuritis. An association of gadolinium leakage with clinical and electrophysiological deficits
62. Microglia-derived macrophages in early multiple sclerosis plaques
63. The application of multifactorial cluster analysis in the staging of plaques in early multiple sclerosis. Identification and characterization of the primary demyelinating lesion
64. A quantitative analysis of oligodendrocytes in multiple sclerosis lesions. A study of 113 cases
65. Multiple sclerosis: Remyelination of nascent lesions
66. Multiple sclerosis: Remyelination in acut lesions
67. Multiple sclerosis: A role for astroglia in active demyelination suggested by class II MHC expression and ultrastructural study
68. Multiple sclerosis. Oligodendrocyte survival and proliferation in an active established lesion
69. Newer magnetic resonance techniques and disease activity in multiple sclerosis: New concepts and new concerns